GENECENTRIX INC.
Biotech · Private
AI-powered reverse drug discovery platform combining Historeceptomics cell/tissue analysis with AlphaFold2 structure prediction and binding affinity algorithms to identify drug targets and candidates
- Grants
- $3.5M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel tool for linking drugs and phenotypes | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel tool for linking drugs and phenotypes | $755,083 | |
| Federal grant | Department of Health and Human Services · Phase I · Crowdsourcing Phenotypes - Diversity Supplement | $12,680 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel tool for linking drugs and phenotypes | $405,083 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel tool for linking drugs to phenotypes - I-Corps Supplement | $40,000 | |
| Federal grant | Department of Health and Human Services · Phase I · BD2K product for enhancing phenotypic screens | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase II · BD2K product for enhancing phenotypic screens | $742,912 | |
| Federal grant | Department of Health and Human Services · Phase II · BD2K product for enhancing phenotypic screens | $729,842 | |
| Federal grant | Department of Health and Human Services · Phase II · Leveraging AI to discover neuron-targeted anti-addiction drugs | $316,719 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1946 | Vero Biotech Inc. | — | $84M |
| 1947 | RAKTA THERAPEUTICS, INC. | — | — |
| 1948 | IGF Oncology, LLC | — | $2.4M |
| 1949 | GENECENTRIX INC. | — | — |
| 1950 | SCALED MICROBIOMICS, LLC | — | — |
| 1951 | RYLTI, LLC | — | $2.3M |
| 1952 | Cargo Therapeutics | — | $69M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.